



## 10x Genomics Announces First Winner of Its Early Career Investigator Award for Excellence in Alzheimer's Disease and Related Dementia Research

August 23, 2021

*Dr. David Gate will receive \$35,000 in 10x Genomics products to further his research*

**PLEASANTON, Calif., August 23, 2021**—Following its call for entries during Alzheimer's awareness month in June, 10x Genomics (Nasdaq: TXG) today has announced the first-ever winner of the 10x Genomics Early Career Investigator Award for Excellence in Alzheimer's Disease and Related Dementia (ADRD) Research. Dr. David Gate, Ph.D., will receive 10x Genomics products valued at \$35,000 to help advance his research efforts into understanding the complex relationship between the immune system and ADRD. Today's announcement took place at the [10x Genomics Global Neurodegenerative Disease Virtual Summit](#), a free online event showcasing research and talks by leading neurological experts from August 23 to 26.

"Neuroscience is a key area in which researchers are making major breakthroughs using single-cell and spatial analysis," said Dr. Kelly Miller, Senior Manager of Neuroscience Segment Marketing at 10x Genomics. "We are endlessly inspired by the achievements our customers are making, and in awarding our first-ever Early Career Investigator Award, we hope to both highlight and support that work in a meaningful way. Our sincere congratulations to Dr. David Gate, and we look forward to following the research you produce throughout your career."

Dr. Gate received his graduate degree in Integrative Biology of Disease from the University of Southern California in 2015. He joined the Wyss-Coray lab in Stanford Neurology as a postdoctoral fellow that same year. Dr. Gate's postdoctoral work identified a seminal role of the adaptive immune system in neurodegenerative disease. Following his postdoctoral work, Dr. Gate joined the Stanford Neurology faculty at the Instructor level, where he developed novel methods to investigate immunity in neurodegeneration. Dr. Gate is now starting an independent laboratory at Northwestern University, where he will serve as Assistant Professor of Neurology beginning September 2021. His lab will focus on the interplay between immune cells and neurodegenerative disease.

"David is a rising star in the field of single cell genomics," said Robert Vassar, Scientific Director of Behavioral Neurology, Northwestern Medicine. "His work published in *Nature* on the role of the adaptive immune system in Alzheimer's disease has made a seminal contribution to the ADRD field. The 10x Genomics Early Career Investigator Award will help David hit the ground running as a newly minted Assistant Professor in Neurology here at Northwestern and get his new research initiated rapidly. I am confident that we will be hearing a lot more about David Gate and his many new discoveries in the future."

The 10x Genomics Early Career Investigator Award focused on individuals with an independent faculty-level position who have not yet received their first major funding award, and are exploring the field of Alzheimer's disease and related dementia. Dr. Gate was selected from more than 160 nominees for this award by a panel of three distinguished experts in the field: Marco Colonna, Ph.D., Professor of Immunobiology and Medicine, Washington University School of Medicine in St. Louis; Bruce Lamb, Ph.D., Executive Director, Stark Neurosciences Research Institute at Indiana School of Medicine; and Michael Heneka, M.D., Professor for Clinical Neurology and Neuroscience, DZNE-Bonn.

"The characterization of T cell responses in Alzheimer's disease and neurodegeneration is an original and innovative concept that is worth pursuing, and David's work in this area is seminal," said Dr. Colonna. "The analysis of T cells may provide insights into potential avenues for therapy in Alzheimer's disease."

In addition to receiving \$35,000 worth of 10x Genomics reagents to further his research, Dr. Gate has been invited to be a keynote speaker at the next 10x Genomics Neurodegenerative Disease Summit in 2022. To learn more about this year's 10x Genomics Global Neurodegenerative Disease Virtual Summit taking place online from August 23 - 26 and register to attend, visit [https://pages.10xgenomics.com/wbr-2021-08-event-ra\\_n-neurodegenerative-week\\_lpseries.html](https://pages.10xgenomics.com/wbr-2021-08-event-ra_n-neurodegenerative-week_lpseries.html).

### About 10x Genomics

10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company's integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2020 based on publications and all of the top 20 global pharmaceutical companies by 2020 research and development spend and have been cited in over 2,800 research papers on discoveries ranging from oncology to immunology and neuroscience. The company's patent portfolio comprises more than 1,150 issued patents and patent applications.

### Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project" "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics product performance, configuration and capabilities and adoption. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors, including the potential impact of the COVID-19

pandemic. Other risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. Although 10x Genomics, Inc. believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics, Inc. as of the date hereof, and 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release.

#### **Disclosure Information**

10x Genomics uses filings with the Securities and Exchange Commission, its website ([www.10xgenomics.com](http://www.10xgenomics.com)), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

#### **Contacts**

Media: [media@10xgenomics.com](mailto:media@10xgenomics.com)

Investors: [investors@10xgenomics.com](mailto:investors@10xgenomics.com)